Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Cells|July 29, 2023
Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted TherapiesAhmad Najem, Mohammad Krayem, Serena Sabbah, et al.
Frontiers in Oncology|December 6, 2021
Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy ResearchMorgane M Cogels, Redouane Rouas, Ghanem E Ghanem, et al.
The Journal of Investigative Dermatology|December 18, 2002
Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptidesManar Moustafa, Marika Szabo, Ghanem E Ghanem, et al.
International Journal of Molecular Sciences|October 27, 2022
Understanding the Radiobiological Mechanisms Induced by <sup>177</sup>Lu-DOTATATE in Comparison to External Beam Radiation TherapyWendy Delbart, Jirair Karabet, Gwennaëlle Marin, et al.
Pigment Cell & Melanoma Research|July 17, 2008
A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse modelKaren M E Dierickx, Renato Morandini, Thi Hien Nguyen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2017
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibitionAhmad Najem, Mohammad Krayem, François Salès, et al.
Molecular Cancer Research : MCR|March 20, 2021
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-KitMalak Sabbah, Mohammad Krayem, Ahmad Najem, et al.
Cancers|May 28, 2020
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic AnalysisLaura Soumoy, Corentin Schepkens, Mohammad Krayem, et al.
Frontiers in Medicine|May 22, 2023
The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanomaMalak Sabbah, Ahmad Najem, Christophe Vanderkerkhove, et al.
Cancers|April 30, 2020
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated MelanomaPauline Tétu, Julie Delyon, Jocelyne André, et al.
Pageof 4